Novo Nordisk stops Ozempic kidney trial after early signs of success | Reuters
Date : 2023-10-10
Description
Against the backdrop of Ozempic's impressive results across many applications, Reuters report on the news that Novo Nordisk will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim analysis that the treatment would succeed.
Read article here
Recently on :
Biotech
Health | Healthcare
WEB - 2023-12-11
AI made from living human brain cells performs speech recognition | NewScientist
NewScientist - Researchers at Indiana University Bloomington have developed a biocomputing system that uses living brain cells ...
WEB - 2023-10-23
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
Verve Therapeutics, a clinical-stage biotechnology company, announced the lifting of the clinical hold and clearance of its IND...
WEB - 2023-10-10
Novo Nordisk stops Ozempic kidney trial after early signs of success | Reuters
Reuters - Novo Nordisk stops a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because i...
WEB - 2023-09-23
Nvidia Buys Illumina? The AI Foundry for Healthcare | Semianalysis
Semianalysis report on the acquisition of Illumina by Nvidia, and use the opportunity to go through all the opportunities of AI...
WEB - 2023-09-17
Illumina: The Measurement Monopoly
Elliot Hershberg explores the story of Illumina, a company that established a Measurement Monopoly in the life sciences by inve...